12:00 AM
 | 
Mar 05, 2012
 |  BioCentury  |  Emerging Company Profile

OncoPep: Smoldering solution

OncoPep developing multi-peptide vaccine for smoldering multiple myeloma

OncoPep Inc. is developing a multi-peptide cancer vaccine for a largely asymptomatic precursor to multiple myeloma. Because these patients remain immunocompetent, they should respond to an immunotherapy, which the company believes could become the treatment of choice based on its anticipated safety profile.

In February, OncoPep announced an exclusive license to PVX-410 from Dana-Farber Cancer Institute. The preclinical candidate contains four immunogenic HLA-A2-specific peptides: two derived from X-box binding protein 1 (XBP1) and one each from cell-surface glycoprotein CS1 and syndecan 1 (SDC1; CD138).

CEO Doris Peterkin told BioCentury XBP1 plays a role in differentiating plasma cells into B cells, "which we believe is a key point in the pathogenesis of myeloma." The other two targets are glycoproteins that exist primarily on the surface of multiple myeloma (MM) cells and are targeted by therapeutics in the clinic for MM.

According to an abstract from a poster presented at the American Society of Hematology meeting in December, the...

Read the full 808 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >